{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:50:00Z","timestamp":1789145400482,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clml.2025.08.017","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T23:11:27Z","timestamp":1756336287000},"page":"94-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World Experience"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7537-0112","authenticated-orcid":false,"given":"Anas","family":"Zayad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2105-2228","authenticated-orcid":false,"given":"Gray","family":"Magee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7029-0985","authenticated-orcid":false,"given":"Mark","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8122-0563","authenticated-orcid":false,"given":"Muhammad Umair","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly M","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Skikne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3168-2521","authenticated-orcid":false,"given":"Zahra Mahmoud","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9182-3931","authenticated-orcid":false,"given":"Jeries","family":"Kort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-7534","authenticated-orcid":false,"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6603-185X","authenticated-orcid":false,"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2025.08.017_bib0001","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.08.017_bib0002","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA: A Cancer J Clinic"},{"issue":"9","key":"10.1016\/j.clml.2025.08.017_bib0003","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.08.017_bib0004","unstructured":"American Journal of Hematology Blood Research Journal Wiley Online Library. Accessed May 16, 2025. https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.27422"},{"key":"10.1016\/j.clml.2025.08.017_bib0005","unstructured":"Myeloma - Cancer Stat Facts. SEER. Accessed May 16, 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"issue":"1","key":"10.1016\/j.clml.2025.08.017_bib0006","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1186\/s12889-025-22240-2","article-title":"Global, regional, and national multiple myeloma burden from 1990 to 2021: a systematic analysis for of the Global Burden of Disease Study 2021","volume":"25","author":"Diao","year":"2025","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.clml.2025.08.017_bib0007","first-page":"3","article-title":"Epidemiology, staging, and management of Multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med Sci (Basel)"},{"issue":"1","key":"10.1016\/j.clml.2025.08.017_bib0008","article-title":"Multiple myeloma incidence and mortality trends in the United States, 1999-2020","volume":"14","author":"Zhu","year":"2024","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.clml.2025.08.017_bib0009","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1200\/JCO.2009.25.4177","article-title":"Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study","volume":"28","author":"Turesson","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.08.017_bib0010","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clml.2025.08.017_bib0011","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1158\/1078-0432.CCR-16-0861","article-title":"Integration of novel agents into the care of patients with multiple myeloma","volume":"22","author":"Orlowski","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.clml.2025.08.017_bib0012","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1586\/14737140.2013.829641","article-title":"Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma","volume":"13","author":"Kuroda","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"10.1016\/j.clml.2025.08.017_bib0013","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"issue":"21","key":"10.1016\/j.clml.2025.08.017_bib0014","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","article-title":"Direct in vitro comparison of Daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79","volume":"124","author":"Lammerts van Bueren","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.08.017_bib0015","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.clml.2025.08.017_bib0016","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via fc\u03b3 receptor\u2013Mediated cross-linking","year":"2025","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.clml.2025.08.017_bib0017","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clml.2025.08.017_bib0018","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V128.22.4531.4531","article-title":"Daratumumab in combination with Lenalidomide plus Dexamethasone induces clonality increase and T-cell expansion: results from a phase 3 randomized study (POLLUX)","volume":"128","author":"Chiu","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.08.017_bib0019","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cyto.a.23693","article-title":"High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with Daratumumab demonstrates immune modulation as a novel mechanism of action","volume":"95","author":"Adams","year":"2019","journal-title":"Cytometry A"},{"issue":"1","key":"10.1016\/j.clml.2025.08.017_bib0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.08.017_bib0021","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for Multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2025.08.017_bib0022","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","year":"2025","journal-title":"New Engl J Med"},{"issue":"26","key":"10.1016\/j.clml.2025.08.017_bib0023","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood-2014-11-611426","article-title":"Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets","volume":"125","author":"Sehgal","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.08.017_bib0024","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.08.017_bib0025","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.08.017_bib0026","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2019000722","article-title":"Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Chari","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.08.017_bib0027","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.clml.2025.08.017_bib0028","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"10245","key":"10.1016\/j.clml.2025.08.017_bib0029","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"The Lancet"},{"issue":"14","key":"10.1016\/j.clml.2025.08.017_bib0030","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.08.017_bib0031","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01440-x","article-title":"Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials","volume":"11","author":"Kiss","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2025.08.017_bib0032","series-title":"Daratumumab-refractory multiple myeloma - Abdallah","year":"2023"},{"issue":"4","key":"10.1016\/j.clml.2025.08.017_bib0033","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2025.08.017_bib0034","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/S2152-2650(21)02318-1","article-title":"P-191: comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple myeloma","volume":"21","author":"Chari","year":"2021","journal-title":"Clin Lymphoma, Myeloma Leukem"},{"key":"10.1016\/j.clml.2025.08.017_bib0035","doi-asserted-by":"crossref","unstructured":"Chng W.J., Wu D.B.C., Wu C.K.W., Springford A., Daly C.H., Jung S.H. Matching-adjusted indirect comparison of Daratumumab-Pomalidomide-Dexamethasone and pomalidomide-Bortezomib-Dexamethasone in relapsed\/refractory multiple myeloma. Clin Lymphoma, Myeloma Leukemia. 2025;0 (0). doi:10.1016\/j.clml.2025.02.007","DOI":"10.2139\/ssrn.5044389"},{"issue":"6","key":"10.1016\/j.clml.2025.08.017_bib0036","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/ejh.14193","article-title":"Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-na\u00efve relapsed multiple myeloma","volume":"112","author":"Dima","year":"2024","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2025.08.017_bib0037","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.3390\/jcm14051655","article-title":"Current treatment strategies for multiple myeloma at first relapse","volume":"14","author":"Mavrothalassitis","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.clml.2025.08.017_bib0038","unstructured":"Multiple myeloma: Treatment of first relapse - UpToDate. Accessed May 27, 2025. https:\/\/www.uptodate.com\/contents\/multiple-myeloma-treatment-of-first-relapse"},{"key":"10.1016\/j.clml.2025.08.017_bib0039","unstructured":"Lodovico Balducci M.D. Myelosuppression and its consequences in elderly patients with cancer. 2003;17. Accessed May 29, 2025. https:\/\/www.cancernetwork.com\/view\/myelosuppression-and-its-consequences-elderly-patients-cancer"},{"issue":"3","key":"10.1016\/j.clml.2025.08.017_bib0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-Associated cardiovascular adverse events","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.clml.2025.08.017_bib0041","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/bloodadvances.2017015545","article-title":"Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials","volume":"2","author":"Chari","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2025.08.017_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14740\/jh1085","article-title":"Adverse hematological and non-hematological events in patients with relapsed\/refractory multiple myeloma that are responsive to Daratumumab, Pomalidomide and Dexamethasone","volume":"12","author":"Alkharabsheh","year":"2023","journal-title":"J Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025028861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025028861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:19:00Z","timestamp":1770650340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025028861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2152265025028861"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}